• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

难治性前列腺癌患者镓 PSMA PET/CT 的超级扫描表现

Superscan Appearance of Ga PSMA PET/CT in a Patient with Refractory Prostate Cancer.

作者信息

Koç Zehra Pınar, Özcan Pınar Pelin, Erçolak Vehbi, Reyhan Mehmet

机构信息

Mersin University Faculty of Medicine, Department of Nuclear Medicine, Mersin, Turkey.

Mersin University Faculty of Medicine, Department of Oncology, Mersin, Turkey.

出版信息

Mol Imaging Radionucl Ther. 2022 Feb 2;31(1):60-62. doi: 10.4274/mirt.galenos.2020.78800.

DOI:10.4274/mirt.galenos.2020.78800
PMID:35114754
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8814547/
Abstract

A 64-year-old male patient with metastatic prostate carcinoma diagnosis received lutetium-177 prostate-specific membrane antigen (PSMA) treatment; however, his disease progressed. Herein, presented the final images of the patient that demonstrated a superscan appearance in the Gallium-68 PSMA positron emission tomography/computed tomography, which is a rare phenomenon.

摘要

一名被诊断为转移性前列腺癌的64岁男性患者接受了镥-177前列腺特异性膜抗原（PSMA）治疗；然而，他的病情仍有进展。在此展示了该患者的最终影像，其在镓-68 PSMA正电子发射断层扫描/计算机断层扫描中呈现出超级扫描表现，这是一种罕见现象。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/72eb/8814547/1991f4d02e5f/MIRT-31-60-g1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/72eb/8814547/1991f4d02e5f/MIRT-31-60-g1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/72eb/8814547/1991f4d02e5f/MIRT-31-60-g1.jpg

相似文献

1
Superscan Appearance of Ga PSMA PET/CT in a Patient with Refractory Prostate Cancer.难治性前列腺癌患者镓 PSMA PET/CT 的超级扫描表现
Mol Imaging Radionucl Ther. 2022 Feb 2;31(1):60-62. doi: 10.4274/mirt.galenos.2020.78800.
2
Metastatic superscan in prostate carcinoma on gallium-68-prostate-specific membrane antigen positron emission tomography/computed tomography scan.镓-68-前列腺特异性膜抗原正电子发射断层扫描/计算机断层扫描上前列腺癌的转移性超级扫描
Indian J Nucl Med. 2016 Apr-Jun;31(2):150-1. doi: 10.4103/0972-3919.178330.
3
Ga-Labeled Prostate-specific Membrane Antigen Ligand Positron Emission Tomography/Computed Tomography for Prostate Cancer: A Systematic Review and Meta-analysis.Ga 标记前列腺特异性膜抗原配体正电子发射断层扫描/计算机断层扫描在前列腺癌中的应用：系统评价和荟萃分析。
Eur Urol Focus. 2018 Sep;4(5):686-693. doi: 10.1016/j.euf.2016.11.002. Epub 2016 Nov 15.
4
68Ga- and 177Lu-Labeled PSMA I&T: Optimization of a PSMA-Targeted Theranostic Concept and First Proof-of-Concept Human Studies.68Ga- 和 177Lu-标记的 PSMA I&T：PSMA 靶向治疗概念的优化及首例概念验证人体研究。
J Nucl Med. 2015 Aug;56(8):1169-76. doi: 10.2967/jnumed.115.158550. Epub 2015 Jun 18.
5
Value of post-therapy Lu-PSMA images for accurate interpretation of therapy response with Ga-PSMA PET/CT.治疗后镥-PSMA图像对于准确解读镓-PSMA PET/CT治疗反应的价值。
Rev Esp Med Nucl Imagen Mol (Engl Ed). 2018 Mar-Apr;37(2):114-117. doi: 10.1016/j.remn.2017.05.004. Epub 2017 Jul 24.
6
More advantages in detecting bone and soft tissue metastases from prostate cancer using F-PSMA PET/CT.使用F-PSMA PET/CT检测前列腺癌骨和软组织转移方面有更多优势。
Hell J Nucl Med. 2019 Jan-Apr;22(1):6-9. doi: 10.1967/s002449910952. Epub 2019 Mar 7.
7
Prostate-Specific Membrane Antigen in Anaplastic and Poorly Differentiated Thyroid Cancer-A New Diagnostic and Therapeutic Target?前列腺特异性膜抗原在间变性和低分化甲状腺癌中——一个新的诊断和治疗靶点？
Cancers (Basel). 2021 Nov 14;13(22):5688. doi: 10.3390/cancers13225688.
8
Ga-PSMA PET/CT in radioactive iodine-refractory differentiated thyroid cancer and first treatment results with Lu-PSMA-617.镓-前列腺特异性膜抗原正电子发射断层扫描/计算机断层扫描在放射性碘难治性分化型甲状腺癌中的应用及镥-前列腺特异性膜抗原-617的首次治疗结果
EJNMMI Res. 2020 Mar 6;10(1):18. doi: 10.1186/s13550-020-0610-x.
9
Unusual Case of Diffuse Penile Metastasis of Prostate Cancer on 68Ga PSMA PET/CT Imaging and 177Lu PSMA Posttherapy Scintigraphy.68Ga PSMA PET/CT 成像与 177Lu PSMA 后治疗闪烁显像显示前列腺癌弥漫性阴茎转移的罕见病例
Clin Nucl Med. 2018 Apr;43(4):276-278. doi: 10.1097/RLU.0000000000002001.
10
ENZA-p trial protocol: a randomized phase II trial using prostate-specific membrane antigen as a therapeutic target and prognostic indicator in men with metastatic castration-resistant prostate cancer treated with enzalutamide (ANZUP 1901).ENZA-p 试验方案：一项随机二期临床试验，以前列腺特异性膜抗原作为治疗靶点和预后指标，评估恩扎卢胺（ANZUP 1901）治疗转移性去势抵抗性前列腺癌男性患者的疗效。
BJU Int. 2021 Nov;128(5):642-651. doi: 10.1111/bju.15491. Epub 2021 Jul 6.

引用本文的文献

1
Superscan on Ga PSMA PET/CT in patients with metastatic prostate carcinoma: A case series.转移性前列腺癌患者镓 PSMA PET/CT 上的超扫描：病例系列
Arch Clin Cases. 2023 Dec 28;10(4):164-170. doi: 10.22551/2023.41.1004.10267. eCollection 2023.

本文引用的文献

1
Combined 18F-FDG PET/CT and 68Ga DOTATATE PET/CT "Superscan" in Metastatic Pancreatic Neuroendocrine Tumor.18F-FDG PET/CT 和 68Ga DOTATATE PET/CT 联合“超级扫描”在转移性胰腺神经内分泌肿瘤中的应用。
Clin Nucl Med. 2017 Feb;42(2):108-109. doi: 10.1097/RLU.0000000000001499.
2
Metastatic superscan in prostate carcinoma on gallium-68-prostate-specific membrane antigen positron emission tomography/computed tomography scan.镓-68-前列腺特异性膜抗原正电子发射断层扫描/计算机断层扫描上前列腺癌的转移性超级扫描
Indian J Nucl Med. 2016 Apr-Jun;31(2):150-1. doi: 10.4103/0972-3919.178330.
3
Secondary Hyperparathyroidism With "Superscan-Like" Hypermetabolic FDG PET/CT Pattern.
继发性甲状旁腺功能亢进伴“超扫描样”高代谢 FDG PET/CT 表现。
Clin Nucl Med. 2015 Nov;40(11):888-9. doi: 10.1097/RLU.0000000000000952.
4
Unusual Bone Superscan, MIBG Superscan, and 68Ga DOTATATE PET/CT in Metastatic Pheochromocytoma.罕见的骨骼超级扫描、MIBG 超级扫描和 68Ga DOTATATE PET/CT 在转移性嗜铬细胞瘤中的应用。
Clin Nucl Med. 2015 Nov;40(11):867-8. doi: 10.1097/RLU.0000000000000920.
5
Metabolic Skeletal Superscan on 18F-FDG PET/CT in a Case of Acute Lymphoblastic Leukemia.18F-FDG PET/CT 代谢性骨骼全身扫描在急性淋巴细胞白血病中的应用
Clin Nucl Med. 2015 Jul;40(7):567-8. doi: 10.1097/RLU.0000000000000785.
6
18F-FDG PET/CT superscan in prostate cancer.18F-FDG PET/CT 全身扫描在前列腺癌中的应用。
Clin Nucl Med. 2014 Oct;39(10):912-4. doi: 10.1097/RLU.0000000000000376.
7
Metabolic super scan in F-FDG PET/CT imaging.代谢物超扫描在 F-FDG PET/CT 成像中的应用。
J Korean Med Sci. 2010 Aug;25(8):1256-7. doi: 10.3346/jkms.2010.25.8.1256. Epub 2010 Jul 21.
8
Absent or faint renal uptake on bone scan. Etiology and significance in metastatic bone disease.
Clin Nucl Med. 1991 Aug;16(8):545-9. doi: 10.1097/00003072-199108000-00002.